Franco Maggiolo
Overview
Explore the profile of Franco Maggiolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
2406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taramasso L, Bonora S, Cingolani A, Di Biagio A, Gianotti N, Guaraldi G, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):610-623.
PMID: 39888371
Modern ART is evolving, allowing the use of new drug formulations and alternative routes of administration to oral therapy. Long-acting (LA) cabotegravir and rilpivirine, the first fully injectable antiretroviral regimen...
2.
L T, Taramasso L, Maggiolo F, F M, Valenti D, D V, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
98(5):484-490.
PMID: 39745743
Introduction: Few data are available on the forgiveness of 2-drug (2DR) or low-barrier 3-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG)...
3.
Maggiolo F, Taramasso L, Valenti D, Blanchi S, Centorrino F, Comi L, et al.
Sex Transm Infect
. 2024 Jul;
100(7):418-422.
PMID: 38964843
: Background : ART forgiveness is the ability of a regimen to maintain HIV-RNA suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). : Methods :...
4.
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, et al.
Int J Antimicrob Agents
. 2024 May;
64(1):107195.
PMID: 38734216
No abstract available.
5.
Orkin C, Antinori A, Rockstroh J, Moreno-Guillen S, Martorell C, Molina J, et al.
AIDS
. 2024 Feb;
38(7):983-991.
PMID: 38349226
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy. Design: Studies 1489 (NCT02607930) and 1490 (NCT02607956) were...
6.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, et al.
BMJ Open
. 2024 Feb;
14(2):e080606.
PMID: 38341206
Purpose: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). Key research...
7.
Maggiolo F, Caputo S, Bonora S, Borderi M, Cingolani A, DEttorre G, et al.
New Microbiol
. 2024 Jan;
46(4):367-380.
PMID: 38252048
Definitive data on the long-term success of the latest antiretroviral therapy (ART) strategies are still lacking. A panel of infectious diseases specialists was convened to develop a consensus on how...
8.
Gagliardini R, Tavelli A, Rusconi S, Caputo S, Spagnuolo V, Santoro M, et al.
Int J Antimicrob Agents
. 2024 Jan;
63(1):107018.
PMID: 38214244
Objectives: Treatment failures to modern antiretroviral therapy (ART) raise concerns, as they could reduce future options. Evaluations of occurrence of multiple failures to modern ART are missing and their significance...
9.
Augello M, Bono V, Rovito R, Tincati C, Bianchi S, Taramasso L, et al.
iScience
. 2024 Jan;
27(1):108673.
PMID: 38188525
Severe COVID-19 outcomes have been reported in people living with HIV (PLWH), yet the underlying pathogenetic factors are largely unknown. We therefore aimed to assess SARS-CoV-2 RNAemia and plasma cytokines...
10.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, et al.
Pharmacol Res
. 2023 Aug;
196:106898.
PMID: 37648103
Background: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and...